Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 75%
filed 2026-06-12
Item 5.02
The disclosure centers on the appointment of J. Colby Williams as Executive Vice President and General Counsel effective September 8, 2026, with detailed terms of his employment agreement including a $1.2M base salary, bonus structure, and equity awards. While Jeffrey T. Welch's retirement as Chief Legal Officer is also disclosed, the substantive focus and length of the filing emphasizes Williams' appointment and compensation terms, making exec_appointment the primary event. The appointment of a senior legal officer with a five-year fixed term and significant equity grants is material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-12
Item 5.07
Xilio Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with voting results on the election of four Class II directors (Bello, Curran, Ross, and Xu), ratification of Ernst & Young LLP as independent auditor, and approval of amendments to the 2021 Stock Incentive Plan regarding prefunded warrant shares.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 72%
filed 2026-06-12
Item 5.02
Stockholders approved an amendment and restatement of the 2021 Stock Incentive Plan, which affects equity grants and awards across the company. A director reclassification (Curran's transition from Class II to Class III) was also disclosed but is administrative in nature.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-12
Item 5.02
BrightSpring Health Services appointed Dr. Nigam H. Shah to its Board of Directors as a Class III director, increasing board size from 7 to 8 members and assigning him to the Quality and Compliance Committee.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 5.03
KLA Corporation announced and effected a ten-for-one forward stock split through a Charter Amendment to its Restated Certificate of Incorporation, which became effective on June 11, 2026. While this is a structural capital event that affects share count and authorized shares, it does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, restatement, auditor change, impairment, covenant breach, or cybersecurity incident). Stock splits are material to investors as they affect share price, trading mechanics, and capitalization structure, warranting disclosure as a material event outside the more specific categories.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-12
Item 5.02
The filing discloses Board approval of base salary ($300,000) and target bonus (40% of base salary) for Ross Ridenoure, Chief Nuclear Officer, following the company's business combination closing. This is a compensatory arrangement disclosure under Item 5.02(e), establishing initial compensation terms for an executive officer in his post-closing role. The materiality reflects that executive compensation arrangements are material to investors assessing management incentives and cost structure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-12
Item 5.02
The filing discloses retention bonus letter agreements entered into on June 10, 2026 with two named executives: Nelson Sun (CFO/COO) receiving $346,500 and Dr. Manasi Jaiman (CMO) receiving $357,000. These are compensatory arrangements—guaranteed annual bonuses and retention bonuses—payable contingent on continued employment or qualifying termination events, which is the hallmark of exec_compensation disclosures under Item 5.02(e).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This Item 5.07 disclosure presents the final voting results from Lumexa Imaging's June 10, 2026 Annual Meeting of Stockholders, including the election of three Class I directors (Lee Cooper, Brian Regan, and Caitlin Zulla) and ratification of PricewaterhouseCoopers LLP as independent auditor, with specific vote tallies for each proposal. The disclosure is a direct and complete shareholder vote results filing as contemplated by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
AMERISAFE held its 2026 Annual Meeting of Shareholders on June 10, 2026, with voting results reported on five matters: election of three directors, an advisory vote on executive compensation, ratification of the independent auditor, and two certificate amendments (one technical amendment approved and one officer exculpation amendment rejected).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of Immunome's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of three Class III directors (Boylan, Swain, Wagenheim), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a Form 8-K Item 5.07 disclosure of shareholder voting results from Janux Therapeutics' June 11, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of two Class II directors (Natasha Hernday and Eric Dobmeier), ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms the election of directors and auditor selection.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
Avista Corporation announced a pause in negotiations with a data center developer and a decision to take additional time evaluating large data center energy requests, citing community concern and the need for a coordinated planning process with governmental agencies. While this does not fit neatly into specific event categories (not M&A completion, not a covenant breach, not litigation), the pause of a material commercial negotiation and the company's public acknowledgment of community opposition and regulatory coordination efforts would affect a reasonable investor's assessment of the company's growth prospects and stakeholder relationships in a capital-intensive utility context.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
Item 1.01
Genasys entered into a $4.3 million unsecured term loan with Maran Partners Fund on June 9, 2026, bearing an 18% fixed interest rate, maturing in three months (September 14, 2026), with substantial fees totaling $365,500 and restrictive covenants. The onerous terms and short maturity suggest financial stress and materially affect the company's liquidity and financial condition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-12
Item 1.01
Mercury General completed a $525 million public offering of 6.250% Senior Notes due 2036 on June 12, 2026, and simultaneously amended its credit agreement to permit this indebtedness. The material covenant structure, including cross-default provisions, makes this a significant financing event affecting the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-12
Item 1.01
MSD Investment Corp. entered into a Third Supplemental Indenture on June 12, 2026, relating to the issuance of $300 million in 6.375% notes due 2029, constituting a material capital-raising event that affects investor assessment of the company's financial position and obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
MSD Investment Corp. entered into a $300 million interest rate swap to hedge its liability structure against its floating-rate asset portfolio, with a three-year term aligned with the Notes maturity and a rate structure of 6.375% fixed versus SOFR+232.5bps, representing a significant financial commitment affecting the company's interest rate exposure and hedging strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear disclosure of shareholder voting results from Vor Biopharma's Annual Meeting held on June 12, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Andrew Levin and Fouad Namouni), approval of an amended 2021 Equity Incentive Plan, and ratification of Ernst & Young LLP as independent auditor. The detailed vote counts for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
Item 8.01
Palmer Square Capital BDC Inc. disclosed management's unaudited estimate of net asset value (NAV) per share as of May 31, 2026 ($13.63). For a Business Development Company, NAV is a key metric for investor valuation and performance assessment. While this appears to be a routine monthly or periodic NAV disclosure typical for BDCs, it is material to investors evaluating the fund's performance and is appropriately disclosed under Item 8.01. The disclosure does not fit more specific event categories (not earnings, not a restatement, not an impairment charge), so other_material is the best fit.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Marblegate Capital Corporation held its Annual Meeting of Stockholders on June 11, 2026, with 94.5% of shares represented. Stockholders voted on and approved four proposals: election of five directors, approval of the 2026 Equity Incentive Plan, ratification of Deloitte & Touche LLP as independent auditor, and approval of meeting adjournment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-12
Item 5.02
The filing discloses both a director departure (Andrew Broderick's resignation effective June 15, 2026) and a director appointment (Barron Steele appointed as Class II director on June 9, 2026). The principal disclosed action centers on the appointment of Steele to fill the vacancy, with detailed disclosure of his compensation (annual cash of $100,000 and initial RSU award of $160,000 prorated), committee assignments, and background. While both events occur, the appointment is the substantive forward-looking action and receives the greater narrative focus.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Sphere Entertainment's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for four proposals: (1) election of directors to the Board (Class A and Class B stockholders voting separately), (2) ratification of the independent auditor, (3) advisory vote on named executive officer compensation, and (4) advisory vote on the frequency of executive compensation votes. The detailed vote tallies (For/Against/Withheld/Abstain/Broker Non-Votes) are the hallmark of shareholder_vote_results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Centessa Pharmaceuticals shareholders voted on June 12, 2026 to approve the acquisition by Eli Lilly under a Scheme of Arrangement, with overwhelming support (126.7 million votes for, ~23,000 against). The Company GM also authorized implementation of the Scheme, and the AGM approved director re-elections and auditor matters.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-12
Item 8.01
Centessa Pharmaceuticals is undergoing a Scheme of Arrangement acquisition by Eli Lilly, with a Court Sanction Hearing scheduled for June 22, 2026. The transaction represents a material change of control and is subject to court approval under UK merger procedures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Annexon's 2026 Annual Meeting held on June 11, 2026. The filing reports voting outcomes on four matters: election of two Class III directors (Bettina M. Cockroft and Douglas Love), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to increase authorized common shares from 300 million to 500 million. All four proposals passed with substantial majorities, making this a material disclosure of shareholder actions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This 8-K Item 5.07 discloses the results of Whitehawk Therapeutics' annual meeting of stockholders held on June 11, 2026, including voting outcomes on three proposals: election of three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve), advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent auditor. The detailed vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Definium Therapeutics held its Annual Meeting on June 11, 2026, with shareholders voting on and approving the election of seven directors, the appointment of KPMG LLP as auditor, and an amendment to the 2025 Equity Incentive Plan increasing available shares by 5,000,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Trinity Capital held its Annual Meeting on June 10, 2026, with stockholders voting on five proposals: director elections (Estes and Zacharia), auditor ratification (Ernst & Young LLP), say-on-pay advisory vote, frequency of future say-on-pay votes, and amendment to the Non-Employee Director Restricted Stock Plan increasing the share pool by 100,000 shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of TKO Group's annual meeting of stockholders held on June 10, 2026. The filing presents voting results for two proposals: election of twelve directors and ratification of KPMG LLP as independent auditor. All director nominees were elected and the auditor ratification was approved, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
Lineage Cell Therapeutics held its annual meeting of shareholders on June 10, 2026, with voting results disclosed for three matters: election of seven directors, ratification of Baker Tilly US, LLP as independent auditor, and advisory approval of named executive officer compensation. Detailed vote tallies including votes for, against, withheld, abstentions, and broker non-votes are provided for each matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the June 9, 2026 annual meeting. The filing reports voting outcomes for two proposals: election of directors (Gino P. Lucadamo and Cecil D. Magpuri as Class III directors) and ratification of KPMG LLP as independent auditor, with detailed vote tallies for each. This is a material event as it reflects stockholder approval of board composition and auditor selection.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-12
Item 1.01
Climb Bio entered into an Open Market Sale Agreement with Jefferies on June 12, 2026, authorizing the sale of up to $100 million in common stock through an at-the-market offering under Rule 415(a)(4), representing a registered dilutive equity issuance that materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-12
Item 8.01
The Company terminated its $22.35 million Equity Distribution Agreement with Oppenheimer & Co. effective June 11, 2026, without incurring penalties and without having sold any shares under the agreement, eliminating a previously-available financing option and signaling a change in the Company's capital strategy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 8.01
Dell Technologies entered into an underwriting agreement on June 11, 2026 to issue $3 billion in senior notes across three tranches (2031, 2034, and 2037 maturities) at specified public offering prices. While this is a material debt issuance that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the more specific event categories (not a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, or dilutive equity issuance). The disclosure is material but represents a routine debt financing activity best classified as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-12
Item 3.02
The filing discloses the acquisition of Newoods, Inc. (ABC Block Company) for $27.2 million in cash plus 587,726 shares of Class A Common Stock. While Item 3.02 typically covers unregistered equity issuances, the substance of this disclosure centers on a material acquisition transaction completed on June 8, 2026. The equity issuance is incidental to the M&A activity, making ma_activity the primary event type, though the dilutive_issuance classification could also apply given the unregistered share component.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This Item 5.07 disclosure reports the results of the 2026 Annual Meeting of Shareholders held on June 10, 2026, including voting outcomes on three matters: (1) election of all nine directors with detailed vote tallies for each nominee, (2) advisory approval of named executive officer compensation with 301.7 million votes for, and (3) ratification of KPMG LLP as independent auditor. The disclosure is a textbook shareholder_vote_results event with complete voting data and outcomes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-12
Item 8.01
Bank of New York Mellon announced redemption of 5,825 shares of Series H Noncumulative Perpetual Preferred Stock and corresponding depositary shares on June 20, 2026. While preferred stock redemptions are routine capital management actions for large financial institutions, the disclosure of a specific redemption date and share count in an 8-K Item 8.01 suggests the company deemed this material enough to report. This does not fit cleanly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-12
Item 1.01
Enliven Therapeutics entered into an underwriting agreement on June 11, 2026 for a registered public offering of 8,933,334 shares of common stock at $37.50 per share, plus 1,733,333 pre-funded warrants, with expected net proceeds of approximately $376 million (or $432.4 million if the underwriter option is exercised in full). The offering will dilute existing shareholders and materially affect the company's capital structure and ownership percentages.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
BigBear.ai held its Annual Meeting on June 9, 2026, with shareholders voting on five proposals: election of directors Kevin McAleenan and Pamela Braden, advisory vote frequency on executive compensation (1-year approved), advisory vote on named executive officer compensation (approved), ratification of Grant Thornton LLP as auditor, and approval of a certificate amendment increasing authorized common shares from 500 million to 1 billion (approved).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This Item 5.07 discloses the results of Evercore's annual meeting of stockholders held on June 10, 2026, including final vote tabulations for four matters: (1) election of 11 directors, (2) say-on-pay advisory vote on named executive officer compensation, (3) ratification of Deloitte & Touche LLP as independent auditor, and (4) approval of the Fourth Amended and Restated 2016 Stock Incentive Plan. All four matters passed with substantial majorities. This is a routine but material disclosure of shareholder voting outcomes required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This 8-K Item 5.07 discloses the final voting results from Apogee Therapeutics' June 9, 2026 Annual Meeting of Stockholders, including three proposals: election of Class III directors (Mark C. McKenna, Jennifer Fox, and William Jones, Jr.), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each proposal are the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-12
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Vroom's Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for three proposals: election of seven directors, ratification of RSM US LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and management accountability.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-06-12
Item 1.01
Super Micro Computer entered into two material equity issuance agreements on June 10-11, 2026: an underwriting agreement to sell approximately 45.5 million shares of common stock (with a 30-day option for an additional 6.8 million shares) and an at-the-market (ATM) distribution agreement for up to $1.25 billion in aggregate sales proceeds. These offerings, including depositary shares representing Series A mandatory convertible preferred stock, represent significant dilutive capital raises that will materially affect existing shareholders' ownership percentages.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project milestone involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance to grid reliability and growth support, and First Nations partnership equity component make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project announcement involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance (grid reliability and growth support), and First Nations partnership model make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-06-12
EX-99.3
The Board authorized a share repurchase program of up to $300 million, with the Company seeking shareholder approval at its June 30, 2026 annual general meeting. The program reflects significant capital allocation strategy and shareholder return policy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-12
Item 7.01
XOMA Royalty Corp announced an expected closing date of July 14, 2026 for its previously announced acquisition by Ligand Pharmaceuticals under a Merger Agreement dated April 27, 2026, constituting a material update on the anticipated completion of a merger transaction that would result in a change of control of the registrant.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-12
Item 8.01
The company announced a full redemption of all outstanding Series A and Series B Cumulative Perpetual Preferred Stock (984,000 and 1,760.5 shares respectively) at $25.00 per share plus accrued dividends, effective July 14, 2026, which will eliminate the preferred equity class and delist the preferred shares from Nasdaq.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-06-12
The 6-K discloses that on June 12, 2026, IFS formally appointed Tanaka, Valdivia, Arribas & Asociados S. Civil de R.L. (EY Perú) as External Auditors for 2026 under an Engagement Letter 2026, following a Master Agreement entered in May 2022. This is a material auditor appointment event, and the registrant explicitly labeled it a "Material Event" in the cover letter. The disclosure confirms EY Perú meets SEC and PCAOB independence criteria and that audit work commenced on June 12, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-06-12
Item 1.01
ERock completed its initial public offering on June 9, 2026, issuing 27.9 million shares of Class A Common Stock at $21.50 per share and raising approximately $600 million in gross proceeds. The IPO involved entry into definitive agreements including the Sixth Amended and Restated LLC Agreement, Tax Receivable Agreement, and Registration Rights Agreement, representing a material change of control and capital structure event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-12
Item 5.02
Seven directors were appointed to ERock's Board of Directors effective June 9, 2026: Charles Boynton, Dan Brouillette, Hans Kobler, Lindsay Luger, Mark Patterson, Sameer Reddy, and Tony Satterthwaite. The appointments occurred in connection with the effectiveness of the Registration Statement and represent a significant governance event for the newly public company.
View raw filing on EDGAR →